Valuation: Novartis AG

Capitalization 302B 261B 235B 226B 412B 27,771B 431B 2,780B 1,114B 13,318B 1,134B 1,110B 47,630B P/E ratio 2026 *
21.6x
P/E ratio 2027 * 19.3x
Enterprise value 335B 289B 261B 250B 456B 30,779B 477B 3,082B 1,235B 14,760B 1,257B 1,230B 52,789B EV / Sales 2026 *
5.8x
EV / Sales 2027 * 5.48x
Free-Float
87.19%
Yield 2026 *
2.79%
Yield 2027 * 2.91%
1 day-1.25%
1 week-5.55%
Current month-5.55%
1 month+2.75%
3 months+15.11%
6 months+18.54%
Current year+12.46%
1 week 121.78
Extreme 121.78
130.4
1 month 119.74
Extreme 119.74
131
Current year 107.68
Extreme 107.68
131
1 year 81.1
Extreme 81.1
131
3 years 73.74
Extreme 73.74
131
5 years 72.84
Extreme 72.84
131
10 years 65.09
Extreme 65.09
131
Manager TitleAgeSince
Chief Executive Officer 50 2018-01-31
Director of Finance/CFO 61 2013-04-23
Chief Tech/Sci/R&D Officer 64 2022-05-15
Director TitleAgeSince
Director/Board Member 68 2014-12-31
Director/Board Member 69 2015-12-31
Director/Board Member 61 2015-12-31
Change 5d. change 1-year change 3-years change Capi.($)
-1.25%-5.55%+22.14%+55.83% 302B
+0.72%-5.86%+13.89%+218.81% 885B
+0.32%-3.23%+44.22%+56.01% 579B
-0.96%-0.85%+7.38%+50.47% 407B
-2.93%-7.03%+11.14%+27.55% 350B
-1.85%-6.70%+20.11%+33.64% 301B
-0.24%-6.49%+22.33%+4.06% 286B
+0.53%-4.80%+13.75%+61.56% 199B
-0.83%-3.37%+22.59%+79.29% 179B
-0.30%+4.20%-58.52%-51.19% 171B
Average -0.68%-3.80%+11.90%+53.60% 365.97B
Weighted average by Cap. -0.46%-4.18%+16.59%+82.54%

Financials

2026 *2027 *
Net sales 57.77B 49.81B 44.96B 43.14B 78.67B 5,309B 82.33B 532B 213B 2,546B 217B 212B 9,105B 60.56B 52.21B 47.13B 45.22B 82.47B 5,565B 86.3B 557B 223B 2,669B 227B 222B 9,545B
Net income 13.92B 12B 10.83B 10.39B 18.95B 1,279B 19.83B 128B 51.29B 613B 52.22B 51.11B 2,193B 15.39B 13.27B 11.98B 11.49B 20.96B 1,414B 21.94B 142B 56.73B 678B 57.77B 56.53B 2,426B
Net Debt 32.73B 28.22B 25.48B 24.44B 44.57B 3,008B 46.65B 301B 121B 1,442B 123B 120B 5,159B 29.79B 25.68B 23.19B 22.25B 40.57B 2,738B 42.46B 274B 110B 1,313B 112B 109B 4,695B
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
75,267
Date Price Change Volume
26-03-06 123.26 CHF -1.25% 3,444,152
26-03-05 124.82 CHF -2.24% 3,521,352
26-03-04 127.68 CHF +1.01% 3,479,655
26-03-03 126.40 CHF -2.74% 4,007,072
26-03-02 129.96 CHF -0.41% 3,782,083
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
158.37USD
Average target price
151.21USD
Spread / Average Target
-4.52%

Quarterly revenue - Rate of surprise